- Home
- SERA vs RIGL Comparison
SERA vs RIGL Comparison
Compare SERA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- RIGL
- Stock Information
- Founded
- SERA 2008
- RIGL 1996
- Country
- SERA United States
- RIGL United States
- Employees
- SERA N/A
- RIGL N/A
- Industry
- SERA Precision Instruments
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SERA Health Care
- RIGL Health Care
- Exchange
- SERA Nasdaq
- RIGL Nasdaq
- Market Cap
- SERA 90.6M
- RIGL 335.5M
- IPO Year
- SERA 2021
- RIGL 2000
- Fundamental
- Price
- SERA $3.10
- RIGL $37.30
- Analyst Decision
- SERA
- RIGL Buy
- Analyst Count
- SERA 0
- RIGL 5
- Target Price
- SERA N/A
- RIGL $38.20
- AVG Volume (30 Days)
- SERA 109.9K
- RIGL 756.0K
- Earning Date
- SERA 11-05-2025
- RIGL 11-06-2025
- Dividend Yield
- SERA N/A
- RIGL N/A
- EPS Growth
- SERA N/A
- RIGL N/A
- EPS
- SERA N/A
- RIGL 5.43
- Revenue
- SERA $108,000.00
- RIGL $267,921,000.00
- Revenue This Year
- SERA $257.66
- RIGL $59.93
- Revenue Next Year
- SERA $435.22
- RIGL N/A
- P/E Ratio
- SERA N/A
- RIGL $6.89
- Revenue Growth
- SERA 0.94
- RIGL 105.62
- 52 Week Low
- SERA $1.37
- RIGL $13.37
- 52 Week High
- SERA $9.13
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- SERA 56.77
- RIGL 53.72
- Support Level
- SERA $2.97
- RIGL $35.56
- Resistance Level
- SERA $3.30
- RIGL $42.65
- Average True Range (ATR)
- SERA 0.31
- RIGL 2.18
- MACD
- SERA -0.00
- RIGL -0.99
- Stochastic Oscillator
- SERA 52.79
- RIGL 24.54
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.